These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors. Zimmer R Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084 [TBL] [Abstract][Full Text] [Related]
4. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Gal S; Abassi ZA; Youdim MB Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083 [TBL] [Abstract][Full Text] [Related]
5. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Cattaneo C; Caccia C; Marzo A; Maj R; Fariello RG Clin Neuropharmacol; 2003; 26(4):213-7. PubMed ID: 12897643 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid. Humphrey SJ; Curry JT; Turman CN; Stryd RP J Cardiovasc Pharmacol; 2001 May; 37(5):548-63. PubMed ID: 11336106 [TBL] [Abstract][Full Text] [Related]
7. [Monoamine oxidase inhibitors and pressor response to dietary amines]. Tipton KF Vopr Med Khim; 1997; 43(6):494-503. PubMed ID: 9503566 [TBL] [Abstract][Full Text] [Related]
8. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669 [TBL] [Abstract][Full Text] [Related]
9. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? Chen JJ; Wilkinson JR J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600 [TBL] [Abstract][Full Text] [Related]
10. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532 [TBL] [Abstract][Full Text] [Related]
11. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine. Abdo-Rubo A Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505 [TBL] [Abstract][Full Text] [Related]
12. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Flanagan S; Bartizal K; Minassian SL; Fang E; Prokocimer P Antimicrob Agents Chemother; 2013 Jul; 57(7):3060-6. PubMed ID: 23612197 [TBL] [Abstract][Full Text] [Related]
13. Monoamine oxidase (MAO)-A but not MAO-B inhibitors potentiate tyramine-induced catecholamine release from PC12 cells. Youdim MB J Neurochem; 1990 Feb; 54(2):411-4. PubMed ID: 2299343 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man. Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810 [TBL] [Abstract][Full Text] [Related]
15. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501 [TBL] [Abstract][Full Text] [Related]
16. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. Patat A; Berlin I; Durrieu G; Armand P; Fitoussi S; Molinier P; Caille P J Clin Pharmacol; 1995 Jun; 35(6):633-43. PubMed ID: 7665725 [TBL] [Abstract][Full Text] [Related]
17. Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction. Pickar D; Cohen RM; Jimerson DC; Lake CR; Murphy DL Psychopharmacology (Berl); 1981; 74(1):8-12. PubMed ID: 6791210 [TBL] [Abstract][Full Text] [Related]
18. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. Bieck PR; Antonin KH J Clin Psychopharmacol; 1988 Aug; 8(4):237-45. PubMed ID: 3209716 [TBL] [Abstract][Full Text] [Related]
20. Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to oral tyramine in man. Martini A; Bonollo L; Nicolis FB; Sega R; Palermo A Br J Clin Pharmacol; 1981 Jun; 11(6):611-5. PubMed ID: 7272178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]